©  ViroCure 2018

#503 AceTwinTower1cha Gurodigital complex

(Or: 212-1 Guro-dong, Guro-gu)

Gurodong, Seoul, Republic of Korea. 08381

Tel: +82 2 861 0316

Fax: +82 2 861 0315

Manbok Kim, Founder

Asst. Professor @ Dankook Univ.

University of Calgary

Oncolytic Virologist

What we do

Naturally occurring viruses are live replication-proficient viruses specifically infecting human cancer cells while sparing their normal counterparts.

 

Since the discovery of naturally oncotropic viruses in the 1920s, various replicating viruses have shown degrees of safety and efficacy in pre-clinical and clinical application for human anti-cancer therapeutics. Cellular oncogenes such as Ras and c-Myc are known to be important host genes for oncolytic viral tropism decision.

 

Importantly, we recently discovered that cellular tumor suppressor genes are also important in determining oncolytic viral tropism. Carcinogenesis is a multi-step process involving accumulation of not only oncogene abnormality but also the accumulation of tumor suppressor gene abnormality. Thus, it is interesting that oncolytic viruses are known to exploit abnormal oncogene and cellular tumor suppressor signaling, frequently dysregulated in various human malignancies, for their decision of oncolytic specificity and efficacy.

 

Unlike oncogenes, many tumor suppressor genes such as p53, ATM, and RB are known to play important roles in genomic fidelity & maintenance. Thus tumor suppressor gene abnormality could affect host genomic integrity and likely disrupt intact antiviral networks due to accumulation of genetic defects resulting in natural viral oncotropism.

 

ViroCure finds naturally occurring oncotropic viruses for targeting various human or animal malignancies, to develop safe and effective treatments to a wide variety of illnesses.

Recent Highlights

April 2019
코스닥 상장기업 EDGC와 투자 및 전략적 협력관계 구축 

April 2018
BSK 인베스트먼트 및 의사협회 등 46억원 pre-A 투자

March 2018
전남생물의약센터(JBRC)에서 임상시험 시료(Clinical Lot) 600 vial 제조 및 보관 전남 화순에 2,000평 GMP 시설 구축위한 용지 확보

September 2017
DT & Investment pre-A 시리즈 투자; 
바이로큐어 미국 연구소 설립 (Moffitt Cancer Center, Tampa, FL and Boston, MA)

July 2017
바이로큐어 중국 염성에 연구소 설립을 위한 준비 계약 체결

November-December 2016
원익투자파트너스 pre-A 시리즈 투자; 오송 바이오밸리에 1,700 평 GMP 시설 구축위한 용지 확보; 바이로큐어㈜ 구로디지탈 단지 본사에 연구소 (BSL2 Lab) 설립

October 2016
슈프리마 인베스먼트(BSK Investment) pre-A 시리즈 투
June-July 2016
바이로큐어 설립 및 엔젤 시드투자

Leadership Team

Haeng Jun Yoo, CEO

CEO, Amicogen, Inc.

President, Jeonbuk Institute for Bioindustry

CEO, CJ Cheiljedang Bio Business Unit 

Samsung Group Chairman's Office

Seoul National University 

Jina Jo, CSO

Assistant Prof. @ Chungnam National Uni.

Harvard Medical School

Wayne State University (Ph.D in Pathology)

Seoul National University

Ju Han Yoon, CTO

C&C Research Labs

Harvard Medical School

Mayo Clinic (Ph.D in Biomed & Immunology)

Korea University

S. Sonny Hwang, CBO

CEO, Modern GMP Co. Ltd.

Sr. Director, Hanmi Pharmaceutical

BD Director, Bayer Korea Ltd.

Associate Director, CJ CheilJedang

University of Texas at Austin

Pusan National University

Scientific Advisory Board

Prof. Chungsoo Kim

ASAN Medical Center

Prostrate Cancer

Prof. Tommy Alain

University of Ottawa

Microbiology & Immunology

Prof. Minhee Ryu

ASAN Medical Center

Medical Oncology

Prof. Jongyon Park

Moffit Cancer Center

Prof. Woochan Son

ASAN Medical Center

Pathology

Veterinary Science

Jade Dennis

Eli Lilly and Company

Oncology

Odonate Therapeutics